Double negatives

American Heart Journal

Volumn 145, Issue 1, 2003, Pages 9-11

  Kandzari, David E ^a,b   Tcheng, James E ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEUKOCYTE ANTIBODY; LEUKOTRIENE B4; NICORANDIL; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PAPAVERINE; THROMBOCYTE ACTIVATING FACTOR; VERAPAMIL;

ANGIOCARDIOGRAPHY; AORTA BALLOON; BLOOD CLOT LYSIS; CONSERVATIVE TREATMENT; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ECHOCARDIOGRAPHY; EDITORIAL; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE FUNCTION; HISTOPATHOLOGY; HUMAN; MEDICAL LITERATURE; MORTALITY; MUSCLE NECROSIS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; ST SEGMENT; SURGICAL TECHNIQUE; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0037217908     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.33     Document Type: Article

References (27)

1. Resnic FS, Wainstein M, Lee MKY, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42-6.
2. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994;90:2514-8.
3. Abbo KM, Dooris M, Glazier S. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-82.
4. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-9.
5. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the "no-reflow" phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-8.
6. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-62.
7. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001;22:729-39.
8. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: Focus on the roles of platelet and inflammatory mediotors in the no-reflow phenomenon. Am J Cardiol 2000;85:50-60B.
9. Sdringola S, Assali AR, Ghani M, et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Cathet Cardiovasc Intervent 2001;54:318-24.
10. Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002;39:591-7.
11. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002;105:1909-13.
12. Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001;38:472-7.
13. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699-705.
14. Porter TR, Li S, Oster R, et al. The clinical implications of no-reflow demonstrated with intravenous perfluorocarbon contoining micro-bubbles following restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction. Am J Cardiol 1998;82:1173-7.
15. Shah A, Wagner GS, Granger CB, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis: Reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol 2000;35:666-72.
16. van't Hof AW, Liem A, de Boer MJ, et al. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial Infarction Study Group. Lancet 1997;350:615-9.
17. Lotan C, Dong S. The no-reflow phenomenon: A light at the end of the tunnel? Cathet Cardiovasc Intervent 2000;51:400-1.
18. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. J Am Coll Cardiol 201;37:1335-43.
19. Hanna GP, Yhip P, Fujise K, et al. Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no-reflow phenomenon. Cathet Cardiovasc Intervent 1999;48:275-8.
20. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous coronary intervention in acute myocardial infarction and reduction in the incidence of the "no-reflow" phenomenon. Cathet Cardiovasc Intervent 2000;51:27-31.
21. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aor-tocoronary vein graft interventions reverses but does not prevent the slow no-reflow phenomenon. Cathet Cardiovasc Intervent 2000;51:394-9.
22. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
23. Giri S, Mitchel JF, Hirst JA, et al. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol 2000;86:269-74.
24. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 198;98:2695-701.
25. de Lemos JA, Antman EM, Gibson M, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation 2000;101:239-43.
26. Baim DS, Wahr D, George B, et al. Randomized trial of distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-90.
27. Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001;104:2436-41.